Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2948MR)

This product GTTS-WQ2948MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2948MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6700MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ9647MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ14241MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ6377MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CSL654
GTTS-WQ290MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ14014MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ3923MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-145
GTTS-WQ15736MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VX-15
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW